Physician profile
Ryan Layman
NPI 1871947846
$1,490.87
in general payments reported to CMS, 2019-2025
24 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $165 · 2022: $495 · 2023: $117 · 2024: $91.86 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $196.68 | 2021-2025 | Parietene Ds |
| Endo Pharmaceuticals INC. | $188.41 | 2021-2024 | Aveed, Xiaflex, Edex |
| Boston Scientific Corporation | $174.78 | 2021-2022 | |
| Pfizer INC. | $139.14 | 2019-2021 | |
| Teleflex LLC | $105.52 | 2022 | |
| Aimmune Therapeutics, INC. | $84.56 | 2025 | Zenpep |
| Olympus America INC. | $69.92 | 2021-2023 | Soltive |
| Calyxo, INC. | $54.99 | 2025 | Cvac Aspiration System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.14 | 2025 | Caplyta |
| Hollister Incorporated | $47.72 | 2022-2024 | Infyna Chic |
| Abbvie INC. | $46.70 | 2025 | |
| Convatec INC. | $44.54 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.41 | 2025 | Eohilia |
| Coloplast Corp | $38.60 | 2023-2025 | Titan |
| Janssen Biotech, INC. | $34.80 | 2025 | Tremfya, Stelara, Simponi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $26.35 | 2025 | Illuccix |
| Xeris Pharmaceuticals, INC. | $24.46 | 2025 | Gvoke Hypopen |
| Vertex Pharmaceuticals Incorporated | $20.81 | 2025 | |
| Lundbeck LLC | $20.24 | 2025 | Vyepti |
| Davol INC. | $20.00 | 2021 | |
| Esperion Therapeutics, INC. | $17.99 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $15.67 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $15.06 | 2025 | Rexulti |
| Abc Home Medical Supply, INC. | $14.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Layman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.